At the ResearchHub SciCon 2023 conference, investor Jason Fang from Sora Ventures spoke about the need for business development in decentralized science.
Fang said a critical risk for decentralized science, also known as DeSci, is its longer time frame compared to other crypto investments. “For us, I think our risk is time. There are so many things we can invest in as crypto investors, and in general, the turnover rate in crypto investments is relatively short compared to traditional investments. [venture capital]” Fang said.
He thinks DeSci needs people skilled in business development to translate research into business opportunities. “One of them is the DeSci. The other one we are extremely bullish on is the Bitcoin utility. I think what we’re going to see is a traditional, traditional health care environment, where we see a lot of the time frame for these gains around the 10-year plus investment line,” Fang said. “That could actually shrink to much shorter than that, maybe to two to three years.”
Fang mentioned Molecule, a DeSci startup, which successfully shortened timelines. “They’re taking out a lot of the bottlenecks, and through a BD game and community game, they’re getting a lot of the resources in the right and more efficient way,” he said. “They’ve actually cut a lot of their delays, which we’re talking about well over 50 percent of the entire life of the study.”
About the cryptocurrency exchanges, Fang said: “I think my goal also in the next few months is to start working, teaching exchanges. I’m going to share the idea that these will actually attract a lot of people to the exchange world. And so you should definitely take a look at the side.”
He believes that stock market listings could provide major funding for DeSci startups. “Once you get involved with some of the top grants, you can basically chip in. On the button it looks like, you basically have no funding, but a lot of funding,” Fang said.
The panel also included Joseph Jacks of OSS Capital, James Brodie of ID Theory and Adam Draper of BoostVC.
Other panelists focused on the need to develop tools and incentives for scientists. However, Fang emphasized that business development is the key to translating innovations into products. The sentiment was well captured in this quote: “In the end, it’s not about who has a better product or who is better; Worse still, there has to be an element of B2B play.”
Disclaimer: Sora Ventures is an investor in CryptoSlate.